ANNALISA CHIAPPELLA

Fondazione IRCCS Istituto Nazionale dei Tumori

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (22)

Collaborators (8)

ANASTASIOS STATHIS

Head of Research Service and Scientific Head Clinical Trial Unit

Istituto Cantonale di Patologia

Alessandro Re

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

Angelica Barone

University of Milan

Giovanna Motta

Istituto Europeo di Oncologia

Giusy Ceparano

Fondazione IRCCS Istituto Nazionale dei Tumori

Gianluca GAIDANO

Professor of Hematology

Silva Ljevar

Fondazione IRCCS Istituto Nazionale dei Tumori

Alejandro Martín García-Sancho

Instituto de Investigación Biomédica de A Coruña

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

ANNALISA CHIAPPELLA

Research Interests

Explore related searches

Contact this professor

Articles (22)

Collaborators (8)

ANASTASIOS STATHIS

Alessandro Re

Angelica Barone

Giovanna Motta

Giusy Ceparano

Gianluca GAIDANO

Silva Ljevar

Alejandro Martín García-Sancho

Make your next move.

ANNALISA CHIAPPELLA

Research Interests

Explore related searches

Contact this professor

Articles (22)

Outcomes of CAR T-cells therapy in High-grade B-cell lymphomas compared to DLBCL: a weighted comparison analysis

Prospective Validation of CAR-HEMATOTOX and a Simplified Version Predict Survival in Patients with Large B-Cell Lymphoma Treated with Anti-CD19 CAR T-Cells: Data from CART-SIE Study

Overcoming barriers to referral for CAR T-cell therapy in patients with non-Hodgkin aggressive B-cell lymphomas: A Delphi Consensus

Brexucabtagene autoleucel in‐vivo expansion and BTKi refractoriness have a negative influence on progression‐free survival in mantle cell lymphoma: Results from CART‐SIE study

Role of bridging RT in relapsed/refractory diffuse large B-cell lymphoma undergoing CAR-T therapy: a multicenter study

A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas

Secondary primary malignancies after CD‐19 directed CAR‐T‐cell therapy in lymphomas: A report from the Italian CART‐SIE study

Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study

Prognostic impact of pretreatment cell‐free DNA concentration in newly diagnosed peripheral T‐cell lymphomas

Out of specification Tisagenlecleucel is associated with outcomes comparable to standard of care product in relapsed or refractory diffuse large B-cell lymphoma

IELSG30 phase 2 trial: intravenous and intrathecal CNS prophylaxis in primary testicular diffuse large B-cell lymphoma

Outcome after chimeric antigen receptor (CAR) T‐cell therapy failure in large B‐cell lymphomas

Romidepsin-CHOEP followed by high-dose chemotherapy and stem-cell transplantation in untreated Peripheral T-Cell Lymphoma: results of the PTCL13 phase Ib/II study

A new frontier for R-CHOP: is two better than one?

Prognostic impact of TP53 mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial

Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma.

Phenotypic composition of commercial anti-CD19 CAR-T cells affects <i>in vivo</i> expansion and disease response in large B-cell lymphoma patients

ALK-negative anaplastic large cell lymphoma: Features and outcomes of 235 patients from the International T-Cell Project

Allogeneic stem cell transplantation in mantle cell lymphoma in the era of new drugs and CAR-T cell therapy

Correction: Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study (Leukemia, (2021), 35, 3, (787-795), 10.1038/s41375-020-01013-3)

Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial

Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study

Collaborators (8)

ANASTASIOS STATHIS

Alessandro Re

Angelica Barone

Giovanna Motta

Giusy Ceparano

Gianluca GAIDANO

Silva Ljevar

Alejandro Martín García-Sancho

Make your next move.